There is a peculiar arithmetic at work in Copenhagen these days: a company raises its full-year outlook, beats on revenue, and still watches its shares slide. Novo Nordisk delivered exactly that paradox on August 4, when second-quarter results showed adjusted sales climbing 7 percent on a constant-currency basis and adjusted operating profit advancing 11 percent to 33.4 billion Danish kroner. The stock, however, has spent the days since drifting lower, trading at roughly 40 euros after shedding 0.6 percent on the day — a move that captures the widening gulf between what the Danish drugmaker reports and what investors are willing to believe.
The market’s skepticism is not without its reasons. The oral version of Wegovy, the pill that was supposed to extend the franchise’s reach beyond injectables, generated 3.2 billion kroner in second-quarter sales — a whisker below the 3.3 to 3.6 billion kroner range analysts had penciled in. In a stock that has been under scrutiny for months, that small miss was enough to sour the mood. The narrative problem is compounded by a pipeline setback that predated the earnings release: on August 1, MT Newswires reported that the Phase 3 trial for Ziltivekimab had failed to reduce major cardiovascular events versus placebo, a blow to the company’s efforts to diversify beyond diabetes and obesity care.
A Two-Sided Ledger
The quarterly numbers themselves tell a more nuanced story than the share price suggests. Revenue came in at 78.5 billion kroner, up 7 percent at constant exchange rates, while the reported operating profit fell 16 percent — a decline driven entirely by 6.3 billion kroner in impairment charges. That mix of operational strength and balance-sheet drag explains why analyst reactions have been unusually split.
The impairments include a 4.0 billion kroner write-down on the obesity candidate Monlunabant, a reminder that not every pipeline asset will make it to market. Yet the company simultaneously raised its 2026 guidance for both sales and operating profit growth to a range of 0 to minus 6 percent at constant currencies, an improvement from the previous minus 12 to minus 4 percent, underpinned by GLP-1 volume momentum.
The Competitive Chessboard
The central question hanging over the stock is whether Novo Nordisk can defend its oral weight-loss franchise against Eli Lilly, which has positioned itself over recent quarters as the more consistent innovator in the obesity space. Berenberg acted on that concern on Wednesday, downgrading the shares from “Buy” to “Hold” and trimming its price target to $47, or 305 Danish kroner, arguing that intensifying competition from Lilly’s oral offerings is already largely priced into the stock.
The REDEFINE-4 trial data for CagriSema, the successor candidate, offered a mixed picture: weight loss comparable to tirzepatide but no superior blood sugar control. Whether that differentiation gap narrows or widens in further analyses will likely carry more weight for the medium-term valuation than any single quarterly print.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Counterweights and Catalysts
The bear case is substantial, but the bull case has its own scaffolding. The European Medicines Agency granted approval in July for the Wegovy pill based on OASIS-4 data, as well as for the high-dose Wegovy 7.2 mg pen based on STEP-UP results — decisions that open additional market segments across Europe. The once-weekly basal insulin Awiqli is now available in the United States, strengthening the diabetes portfolio beyond weight care. And a strategic partnership with Amazon Web Services aims to accelerate drug discovery and clinical development through artificial intelligence, with a co-innovation hub planned at Novo’s King’s Cross site in London.
Management is also putting money behind its convictions. The ongoing buyback program, authorized for up to 15 billion kroner over twelve months since February 4, had repurchased nearly 27.9 million B-shares by August 7, including roughly 820,000 additional shares between August 4 and 7. Zacks Research offered a modest vote of confidence on Wednesday, lifting its rating from “Strong Sell” to “Hold.”
Reading the Tape
The chart tells its own version of events. The stock sits roughly 27 percent below its 52-week high of 54.86 euros, reached in January, and has fallen 9.1 percent year to date. The 30-day decline stands at 6.8 percent. Yet the shares are hovering just beneath their 200-day moving average of 40.30 euros — a sign that the downward momentum may be stabilizing, even if the 50-day average remains 3.7 percent above the current price.
What makes this moment unusual is not the disappointment itself but the market’s refusal to reward improvement. Novo Nordisk has done what companies are supposed to do in difficult stretches: raised guidance, maintained buybacks, secured regulatory approvals, and advanced its pipeline. None of it has been enough to reverse the sentiment tide. The market appears to be demanding something more exacting — proof that each pipeline project will deliver, because the competitive landscape no longer grants breathing room.
The next meaningful data points will come from further CagriSema readouts and competitive developments in the oral weight-loss segment. Until then, the stock’s trajectory will likely be shaped less by what Novo Nordisk says about itself and more by what Eli Lilly does next.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 13 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 13.
Novo Nordisk: Buy or sell? Read more here...
